Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

74 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
An Incomplete Prescription: President Trump's Plan to Address High Drug Prices.
Sarpatwari A, Avorn J, Kesselheim AS. Sarpatwari A, et al. JAMA. 2018 Jun 19;319(23):2373-2374. doi: 10.1001/jama.2018.7424. JAMA. 2018. PMID: 29800027 No abstract available.
Using a drug-safety tool to prevent competition.
Sarpatwari A, Avorn J, Kesselheim AS. Sarpatwari A, et al. N Engl J Med. 2014 Apr 17;370(16):1476-8. doi: 10.1056/NEJMp1400488. N Engl J Med. 2014. PMID: 24738666 No abstract available.
Ensuring patient privacy in data sharing for postapproval research.
Sarpatwari A, Kesselheim AS, Malin BA, Gagne JJ, Schneeweiss S. Sarpatwari A, et al. N Engl J Med. 2014 Oct 23;371(17):1644-9. doi: 10.1056/NEJMsb1405487. N Engl J Med. 2014. PMID: 25337755 No abstract available.
Paying physicians to prescribe generic drugs and follow-on biologics in the United States.
Sarpatwari A, Choudhry NK, Avorn J, Kesselheim AS. Sarpatwari A, et al. PLoS Med. 2015 Mar 17;12(3):e1001802. doi: 10.1371/journal.pmed.1001802. eCollection 2015 Mar. PLoS Med. 2015. PMID: 25781468 Free PMC article.
Progress and Hurdles for Follow-on Biologics.
Sarpatwari A, Avorn J, Kesselheim AS. Sarpatwari A, et al. N Engl J Med. 2015 Jun 18;372(25):2380-2. doi: 10.1056/NEJMp1504672. Epub 2015 May 6. N Engl J Med. 2015. PMID: 25946143 No abstract available.
The 21st century cures act: Opportunities and challenges.
Sarpatwari A, Kesselheim AS. Sarpatwari A, et al. Clin Pharmacol Ther. 2015 Dec;98(6):575-7. doi: 10.1002/cpt.208. Epub 2015 Oct 8. Clin Pharmacol Ther. 2015. PMID: 26264909
Such strong bipartisan support, rare in an age of congressional gridlock, might logically be interpreted as a sign of the Act's promise to foster innovative drug and device development. However, careful inspection reveals that while the Act contains some positive features, …
Such strong bipartisan support, rare in an age of congressional gridlock, might logically be interpreted as a sign of the Act's promi …
Experience With the Priority Review Voucher Program for Drug Development.
Kesselheim AS, Maggs LR, Sarpatwari A. Kesselheim AS, et al. JAMA. 2015 Oct 27;314(16):1687-8. doi: 10.1001/jama.2015.11845. JAMA. 2015. PMID: 26414802 No abstract available.
Regulatory Solutions to the Problem of High Generic Drug Costs.
Luo J, Sarpatwari A, Kesselheim AS. Luo J, et al. Open Forum Infect Dis. 2015 Nov 13;2(4):ofv179. doi: 10.1093/ofid/ofv179. eCollection 2015 Dec. Open Forum Infect Dis. 2015. PMID: 26693494 Free PMC article.
Recent reports have highlighted dramatic price increases for several older generic drugs, including a number of essential products used to treat deadly infectious diseases. ...
Recent reports have highlighted dramatic price increases for several older generic drugs, including a number of essential products us …
The Case for Reforming Drug Naming: Should Brand Name Trademark Protections Expire upon Generic Entry?
Sarpatwari A, Kesselheim AS. Sarpatwari A, et al. PLoS Med. 2016 Feb 9;13(2):e1001955. doi: 10.1371/journal.pmed.1001955. eCollection 2016 Feb. PLoS Med. 2016. PMID: 26859662 Free PMC article. Review.
Ameet Sarpatwari and Aaron Kesselheim explore whether stripping branded drugs of trademark protection would improve the efficiency and fairness of health care....
Ameet Sarpatwari and Aaron Kesselheim explore whether stripping branded drugs of trademark protection would improve the efficiency an …
Ethical and Practical Considerations in Removing Black Box Warnings from Drug Labels.
Yeh JS, Sarpatwari A, Kesselheim AS. Yeh JS, et al. Drug Saf. 2016 Aug;39(8):709-14. doi: 10.1007/s40264-016-0419-8. Drug Saf. 2016. PMID: 27000800
Boxed warnings-also known as "black box" warnings-can be a powerful tool in communicating drug risks to physicians and patients. ...For ethical and practical reasons, the FDA is justified in applying a higher standard for boxed warning removal than for imposition, a …
Boxed warnings-also known as "black box" warnings-can be a powerful tool in communicating drug risks to physicians and patients. ...F …
74 results
Jump to page
Feedback